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RESUMO – As dermatoses degenerativas induzidas por D-penicilamina incluem, entre outras, a elastose perfurante serpiginosa 
e o pseudo-pseudoxantoma elástico. A elastose perfurante serpiginosa é uma doença perfurante rara caracterizada pela elimi-
nação transepidérmica de fibras elásticas anormais. Esta condição pode ser idiopática, reativa ou induzida por D-penicilamina, 
habitualmente utilizada para o tratamento da doença de Wilson, cistinúria, artrite reumatóide ou esclerose sistémica. Manifesta-
ções cutâneas semelhantes a pseudoxantoma elástico mas sem história familiar e mutações do gene ABCC6 foram identificadas 
como sendo uma dermatose induzida por D-penicilamina e designada de pseudo-pseudoxantoma elástico.
Descreve-se o caso de uma mulher de 17 anos tratada por vários anos com D-penicilamina para doença de Wilson, com pápulas 
assintomáticas, algumas cor de pele e hiperqueratósicas e outras macias e amareladas, na região cervical e face. A histopatolo-
gia mostrou a eliminação transepidérmica de fibras elásticas espessadas, em forma de dentes de serra. Estes achados sugeriram 
uma dermopatia induzida por D-penicilamina e os autores consideraram o diagnóstico de elastose perfurante serpiginosa e 
pseudo-pseudoxantoma elástico no mesmo paciente. O fármaco foi alterado para acetato de zinco sem lesões novas, mas com 
manutenção das lesões existentes no seguimento a 1 ano.  
PALAVRAS-CHAVE – Penicilamina/efeitos adversos; Degeneração Hepatolenticular; Doenças da Pele/induzidas quimicamente; 
Pseudoxantoma Elástico.
D-Penicillamine Induced Degenerative Dermopathy 
in a Patient with Wilson Disease
ABSTRACT – D-penicillamine induced degenerative dermatosis include, among others, elastosis perforans serpiginosa, and pseudo-
-pseudoxanthoma elasticum. Elastosis perforans serpiginosa is a rare perforating disease characterized by transepidermal elimi-
nation of abnormal elastic fibers. This condition can be idiopathic, reactive or induced by D-penicillamine, commonly used for the 
treatment of Wilson disease, cystinuria, rheumatoid arthritis or systemic sclerosis. Cutaneous manifestations resembling pseudoxan-
thoma elasticum but lacking familiar history and ABCC6 mutations have been identified as a D-penicillamine induced dermopathy 
and called pseudo-pseudoxanthoma elasticum.
The authors present a 17-year-old caucasian female treated for several years with D-penicillamine for Wilson disease who deve-
loped asymptomatic papules, some hyperkeratotic skin-colored and other soft and yellowish, on the cervical region and face. His-
topathology showed transepidermal elimination of numerous, branched, sawtooth-like elastic fibers. These findings suggested a 
D-penicillamine induced dermopathy and the authors considered the diagnosis of both elastosis perforans serpiginosa and pseudo-
-pseudoxanthoma elasticum in the same patient. The drug was switched to zinc acetate. No newer lesions appeared thereafter but 
previous lesions persisted at the 1 year follow-up.
KEYWORDS – Penicillamine/adverse effects; Hepatolenticular Degeneration; Pseudoxanthoma Elasticum; Skin Diseases/chemically 
induced. 
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INTRODUCTION 
D-penicillamine induced degenerative dermatosis includes 
elastosis perforans serpiginosa (EPS), pseudoxanthoma elasti-
cum-like skin changes or pseudo-pseudoxanthoma elasticum 
(PPXE), acquired cutis laxa and anetoderma.1
Elastosis perforans serpiginosa is a rare perforating disea-
se characterized by transepidermal elimination of abnormal 
elastic fibers. This condition is typically found in adolescents 
and young adults with a male preponderance.2 EPS has been 
classified as idiopathic, reactive or drug-induced.3-5 It is usually 
an isolated condition but has also been associated with other 
diseases like Down´s syndrome, Marfan syndrome, morphea, 
systemic sclerosis, cutis laxa and pseudoxanthoma elasticum 
(PXE).6 The only drug known to induce EPS is D-penicillamine, 
a heavy metal chelator still commonly used in the treatment of 
Wilson disease (WD), cystinuria, rheumatoid arthritis or syste-
mic sclerosis.1,7
Pseudoxanthoma elasticum is an autosomal recessive di-
sorder characterized by progressive mineralization and frag-
mentation of elastic fibers in various systems: skin (yellowish 
papules, “cobblestoning,” and redundant folds in flexural 
areas), eyes (angioid streaks and retinal defects) and cardio-
vascular system (renovascular hypertension, angina pectoris, 
myocardial infarction, and stroke).8 Cutaneous manifestations 
resembling PXE without familiar history and ABCC6 mutations 
have been identified as a D-penicillamine induced dermopa-
thy. These pseudoxanthoma elasticum-like skin changes are 
also known as pseudo-pseudoxanthoma elasticum.
The authors present a case of a D-penicillamine induced 
dermopathy in a young adult female with WD treated for seve-
ral years with D-penicillamine, that poses a difficult distinction 
between EPS and PPXE and is probably an association of both 
entities.
CASE PRESENTATION
A 17-year-old caucasian female patient affected with WD 
from the age of 5 and treated since then with D-penicillamine 
at daily doses ranging from 900 mg to 4 g. There were no 
hepatic or neurologic manifestations of WD. There was no re-
levant family history. 
The patient was presented to our Dermatology department 
with a one year history of multiple, progressively appearing, 
asymptomatic papules located in the cervical region.
The clinical observation revealed multiple discrete, small, 
skin-colored to yellowish papules, some hyperkeratotic, others 
soft to palpation, distributed through the neck and in a smaller 
number, on the face (Fig 1). In addition, there was an atrophic 
lesion with a poorly defined arciform border and telangiectasia 
of about 1.5 cm located on the right cervical area (Fig. 2). No 
lesions were seen in other locations.
The patient was previously treated topically for acne vulga-
ris without any improvement.
Histopathology from an incisional skin biopsy on the cervical 
plaque revealed an acanthotic, hyperkeratotic epidermis; tran-
sepidermal elimination of numerous, branched, sawtooth-like 
elastic fibers; a mixed dermal inflammatory infiltrate and some 
multinucleated giant cells (Fig.s 3-4). These findings sugges-
ted a D-penicillamine induced dermopathy. From the clinico-
pathological correlation a diagnosis of penicillamine-induced 
dermatosis consisting of mixed findings of EPS and PPXE was 
made.
Echocardiogram and ECG were normal. No other exams 
were performed due to the lack of symptomatic complaints or 
clinical findings.
D-penicillamine was switched to zinc acetate 50 mg 3 id 
with good control of WD. 
At 1 year follow-up, however, cutaneous lesions still persist 
but no newer papules appeared.
DISCUSSION
Wilson disease is an autosomal recessive disorder caused 
by a mutation in the gene ATP7B that encodes a protein expres-
sed on hepatocytes and involved in the excretion of copper into 
the bile.9 In WD copper is accumulated in the liver, brain and 
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Figure 1 - Multiple discrete skin-colored papules in the neck. 
Figure 2 - Atrophic lesion with a poorly defined arciform border and 
telangiectasia on the right cervical area. 
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eye damaging these organs and causing potentially threate-
ning complications.9
The D enantiomer of penicillamine is a well-known heavy 
metal chelator used as a therapeutic option in several different 
diseases like WD, cystinuria, rheumatoid arthritis or systemic 
sclerosis.1 Although the clinical outcome is good, D-penicilla-
mine is known to cause many adverse effects, both cutaneous 
and extracutaneous.1 Approximately half the patients will have 
a side effect within the first 6 months and up to one-third will 
have to discontinue the drug.10 Cutaneous adverse effects are 
the most prevalent occurring in up to 50% of patients and lea-
ding to drug withdrawal in 10% of patients.11 There are four 
types of penicillamine-induced dermatosis: 1) acute hypersen-
sitive reactions, including urticaria; 2) dermopathies charac-
terized by elastic fibers abnormalities (like EPS and PPXE); 3) 
auto-immune disorders including bullous and connective tissue 
disorders and 4) miscellaneous dermatosis (lichen planus, pso-
riasiform dermatitis, alopecia and nail changes).1 
About 1% of the patients treated with penicillamine for de-
cades will develop EPS.12
The current theory is that D-penicillamine induces 
abnormalities in elastic fibers similar to EPS and PPXE essen-
tially by two mechanisms: 1) direct interference with tropocolla-
gen cross-linking (this applies only to soluble collagen and not 
mature insoluble collagen which may explain why certain le-
sions take years to become apparent and others appear after 
the drug withdrawal); 2) inhibition of lysil oxidase, a copper 
dependent enzyme that catalyses the cross-linking of elastic 
and collagen fibers.1 These processes result in unstable elastic 
fibers that may be extruded in a foreign body reaction-like me-
chanism.2,7,12 This phenomenon can theoretically occur in any 
location with elastic fibers like the skin, lung, pharyngeal tissue, 
artery walls, joint capsules or cervical connective tissue.1
Clinically EPS occurs as asymptomatic, erythematous to 
skin-colored, hyperkeratotic papules usually arranged in an-
nular or serpiginous configuration that can occur anywhere on 
the body surface but are typically found in the neck and upper 
extremities.6,7 D-penicillamine induced EPS lesions are clini-
cally indistinguishable from the idiopathic form of the disease.1
Cutaneous findings of PPXE are clinically similar to those of 
PXE but there is neither a positive familiar history of the disease 
nor the presence of the mutations of the ABCC6 gene.13 Also, 
there is an important histological difference: in PPXE there is 
no evidence of calcium deposition on the dermal elastic fibers, 
which is a critical factor in the pathogenesis of the disease.13 
PPXE findings include a “plucked-chicken skin” appearance 
on the neck and in the axillae with excessive wrinkling and 
elastotic papules and redundant skin folds in flexural areas.13 
The typical yellow discoloration of the PPXE and PXE lesions is 
due to the presence of elevated quantities of abnormal dermal 
elastic fibers.13
In the patient described there were some soft, yellowish 
papules similar to PPXE but other sites of involvement and re-
dundant folds in flexural areas were lacking. Also, the “plu-
cked-chicken skin” was not evident. On the other side, the 
hyperkeratotic skin-colored papules on the neck are suggestive 
of EPS. Although the traditional annular or serpiginous distri-
bution was not present, there are reports of isolated papules 
on EPS cases.14 In our patient, we observed an atrophic plaque 
that may be a sequelar finding of an annular plaque. Before 
this, the authors considered that three diagnostic options were 
viable: atypical EPS, atypical PPXE or a combination of both. 
There are a few reports in the literature supporting this latter 
option.8,15,16
The histopathology of these diseases are similar and 
usually show an acanthotic, hyperkeratotic epidermis with 
a mixed dermal inflammatory infiltrate and few giant cells.7 
Atrophy of the skin can be found at the center of EPS lesions.7 
Transepidermal perforating channels extend from the dermis 
and contain a mixture of eosinophilic elastic fibers, basophilic 
debris and inflammatory cells.2 In drug induced EPS, elastic 
fiber stain shows thickened serrated morphology resulting in 
the typical “lumpy-bumpy” or “bramble-bush” pattern both in 
lesional and non-lesional skin.17,18
EPS and PPXE lesions usually arise after several decades of 
D-penicillamine medication, have a chronic course and can 
even arise after drug withdrawal. Spontaneous resolution has 
been described several months after drug withdrawal.19 Al-
though there is no effective treatment for D-penicillamine indu-
ced dermopathies the best option seems drug suspension and 
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Figure 3 - H&E 100x - Acanthotic epidermis and transepidermal elimi-
nation of elastic fibers. Mixed dermal inflammatory infiltrate.
Figure 4 - Orcein staining of elastic fibers 100x - Transepidermal 
elimination of numerous, branched, sawtooth-like elastic fibers.
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switch to another medication of the underlying disease.20 For 
WD the main options are trientine or zinc, both with good re-
sults.9 In our patient the underlying WD remained well control-
led with zinc acetate and no newer lesions appeared for one 
year. However, a few of the previously existing lesions remain.
In conclusion, we present this case of D-penicillamine in-
duced dermatosis to illustrate the importance of recognition 
of these lesions, which may be subtle and usually asymp-
tomatic and to highlight that due to the slow penicillamine 
metabolism, lesions can persist or even arise even after drug 
withdrawal. Although the association of true PXE and EPS is 
well recognized, the presence in the same patient of lesions 
clinically compatible with both EPS and PPXE induced by peni-
cillamine is a rare event with few reports in the literature.
Conflitos de interesse: Os autores declaram não possuir con-
flitos de interesse. 
Suporte financeiro: O presente trabalho não foi suportado 
por nenhum subsídio ou bolsa. 
Confidencialidade dos dados: Os autores declaram ter segui-
do os protocolos do seu centro de trabalho acerca da publica-
ção dos dados de doentes. 
Protecção de pessoas e animais: Os autores declaram que 
os procedimentos seguidos estavam de acordo com os regula-
mentos estabelecidos pelos responsáveis da Comissão de In-
vestigação Clínica e Ética e de acordo com a Declaração de 
Helsínquia da Associação Médica Mundial. 
Conflicts of interest: The authors have no conflicts of interest 
to declare. 
Financing Support: This work has not received any contribution, 
grant or scholarship. 
Confidentiality of data: The authors declare that they have 
followed the protocols of their work center on the publication 
of data from patients. 
Protection of human and animal subjects: The authors declare 
that the procedures followed were in accordance with the re-
gulations of the relevant clinical research ethics committee and 
with those of the Code of Ethics of the World Medical Associa-
tion (Declaration of Helsinki). 
REFERÊNCIAS
1. Ishak R, Abbas O. Penicillamine revisited: historic over-
view and review of the clinical uses and cutaneous adver-
se effects. Am J Clin Dermatol. 2013;14:223-33.
2. Lewis KG, Bercovitch L, Dill SW, Robinson-Bostom L. Ac-
quired disorders of elastic tissue: part I. Increased elastic 
tissue and solar elastotic syndromes. J Am Acad Derma-
tol. 2004;51:1-21; quiz 2-4.
3. Vearrier D, Buka RL, Roberts B, Cunningham BB, Ei-
chenfield LF, Friedlander SF. What is standard of care 
in the evaluation of elastosis perforans serpiginosa? A 
survey of pediatric dermatologists. Pediatr Dermatol. 
2006;23:219-24.
4. Langeveld-Wildschut EG, Toonstra J, van Vloten WA, 
Beemer FA. Familial elastosis perforans serpiginosa. 
Arch Dermatol. 1993;129:205-7.
5. Patterson JW. The perforating disorders. J Am Acad Der-
matol. 1984;10:561-81.
6. Castro Pinho A, Cardoso JC, Gouveia M, Oliveira H. 
Elastose Perfurante serpiginosa e doenca de wilson: 
uma consequencia rara, mas previsivel da terapeuti-
ca a longo prazo com D-penicilamina. Acta Med Port. 
2016;29:227-30.
7. Hellriegel S, Bertsch HP, Emmert S, Schon MP, Haenssle 
HA. Elastosis perforans serpiginosa: a case of a penici-
llamine-induced degenerative dermatosis. JAMA Derma-
tol. 2014;150:785-7.
8. Rath N, Bhardwaj A, Kar HK, Sharma PK, Bharadwaj 
M, Bharija SC. Penicillamine induced pseudoxanthoma 
elasticum with elastosis perforans serpiginosa. Indian J 
Dermatol Venereol Leprol. 2005;71:182-5.
9. Ranucci G, Di Dato F, Leone F, Vajro P, Spagnuolo MI, 
Iorio R. Penicillamine-induced elastosis perforans serpi-
ginosa in Wilson disease: is useful switching to zinc?  J 
Pediatr Gastroenterol Nutr. 2017;64:e72-e73
10. Shiokawa Y, Horiuchi Y, Honma M, Kageyama T, Okada 
T, Azuma T. Clinical evaluation of D-penicillamine by 
multicentric double-blind comparative study in chronic 
rheumatoid arthritis. Arthritis Rheum. 1977;20:1464-72.
11. Bialy-Golan A, Brenner S. Penicillamine-induced bullous 
dermatoses. J Am Acad Dermatol. 1996;35:732-42.
12. Tovaru S, Parlatescu I, Dumitriu AS, Bucur A, Kaplan I. 
Oral complications associated with D-penicillamine 
treatment for Wilson disease: a clinicopathologic report. 
J Periodontol. 2010;81:1231-6.
13. Bolognia JL, Braverman I. Pseudoxanthoma-elasticum-li-
ke skin changes induced by penicillamine. Dermatology. 
1992;184:12-8.
14. Bennett JA, Clarke JT, Ioffreda MD. Annular kerato-
tic papules on the extremities. J Am Acad Dermatol. 
2015;73:891-3.
15. Becuwe C, Dalle S, Ronger-Savle S, Skowron F, Balme 
B, Kanitakis J, et al. Elastosis perforans serpiginosa as-
sociated with pseudo-pseudoxanthoma elasticum during 
treatment of Wilson's disease with penicillamine. Derma-
tology. 2005;210:60-3.
16. Meyrick Thomas RH, Kirby JD. Elastosis perforans ser-
piginosa and pseudoxanthoma elasticum-like skin 
change due to D-penicillamine. Clin Exp Dermatol. 
1985;10:386-91.
17. Bergman R, Friedman-Birnbaum R, Ludatscher R, Li-
chtig C. An ultrastructural study of the reactive type 
of elastosis perforans serpiginosa. Arch Dermatol. 
1987;123:1127-9.
18. Bardach H, Gebhart W, Niebauer G. "Lumpy-bumpy" 
elastic fibers in the skin and lungs of a patient with a 
penicillamine-induced elastosis perforans serpiginosa. J 
Cutan Pathol. 1979;6:243-52.
19. Deguti MM, Mucenic M, Cancado EL, Tietge UJ. Elasto-
sis perforans serpiginosa secondary to D-penicillamine 
treatment in a Wilson's disease patient. Am J Gastroente-
rol. 2002;97:2153-4.
20. Wang D, Liang J, Xu J, Chen L. Effective treatment of d-pe-
nicillamine induced elastosis perforans serpiginosa with 
ALA-PDT. Photodiagnosis Photodyn Ther. 2015;12:140-2.
Revista SPDV 76(2) 2018; D-Penicillamine induced degenerative dermopathy; Rui Pedro Santos, Joana Gomes, Celeste Brito.
